Work

Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents

Year: 2018

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2018-99-113840

Authors: Justin Taylor, Morgan Coleman, Kelsey Alvarez, Janine Pichardo, Filiz Sen, Stephen S. Chung, Raajit K. Rampal, Jae H. Park, Eytan M. Stein, Martin S. Tallman, Omar I Abdel-Wahab, Virginia M. Klimek

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2905037315

Cites:

Cited by: 6

Related to: 10